Cancer · 1993 · 16 citations · 26 references
MedicineOncologyCancer Drug Toxicity ManagementChemotherapyGynecologic OncologyCervical CancerChemotherapy ResistanceChemotherapy Toxicity ManagementCombination ChemotherapySquamous Cell CarcinomaToxicity ManagementCervical Cancer ChemotherapyCervical RecurrenceComplete Response AssessmentPartial Response AssessmentPhase Ii InvestigationPlatinum-based RegimensRecurrent Cervical CancerRecurrent Cervical Neoplasia
BACKGROUND: Ifosfamide is an active agent in cisplatin-resistant cervical cancer. To determine the response rate of the combination of cisplatin and ifosfamide, a Phase II study was conducted of the administration of the combination after weekly cisplatin induction therapy. METHODS: Forty-seven patients with advanced or recurrent cervical carcinoma were treated with 1 mg/kg of cisplatin weekly for six courses, followed by 20 mg/m2 of cisplatin and 1.2 g/m2 of ifosfamide daily for 3 days every 28 days. RESULTS: Objective responses were seen in 11 of 40 (27.5%) assessable patients (complete response, 20%; partial response, 7.5%). The duration of response ranged from 3 months to 26+ months (median, 9+ months). All of the patients who responded to the cisplatin-ifosfamide combination initially responded to weekly cisplatin induction therapy. None of the four patients who had previously received chemotherapy responded. Grade 3 or 4 hematologic toxic effects occurred in 17 of 43 patients (39%). Neurologic and urologic toxic effects were infrequent. The current response rates are not better than the prior experience of the authors with other cisplatin combinations. CONCLUSIONS: These results do not confirm the favorable reports of other authors with cisplatin-ifosfamide regimens in cervical carcinoma. The results of ongoing Phase III studies comparing cisplatin-ifosfamide with cisplatin alone in cervical carcinoma are awaited.
26
J.T. Thigpen, John A. Blessing, Philip J. DiSaia et al. · Gynecologic Oncology · 1989 · 121 citations
Medicine, Gynecology, Oncology +10
David S. Alberts, Richard A. Kronmal, Lawrence Baker et al. · Journal of Clinical Oncology · 1987 · 80 citations
Medicine, Oncology, Pharmacology +14